• Antiarrhythmic Drugs and SK Channel Modulation in Atrial Fib

  2026-07-16

  This study systematically evaluates whether clinically recommended antiarrhythmic drugs (AADs) for atrial fibrillation (AF) inhibit small conductance calcium-activated potassium (KCa2.X/SK) channels, a proposed atrial-specific target. The findings reveal that, with the exception of dofetilide and propafenone at non-therapeutic concentrations, current AADs do not significantly inhibit human SK channels, highlighting the need for more selective atrial therapies.

• Applied Workflows with Angiotensin I: Protocols and Troubles

  2026-07-16

  Leverage Angiotensin I (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) to unlock high-fidelity modeling of the renin-angiotensin system and accelerate antihypertensive drug screening. This article delivers optimized protocols, advanced experimental insights, and actionable troubleshooting strategies—grounded in both product data and cutting-edge spectral analysis research.

• Myriocin Reverses dAGE-Induced Metabolic Dysfunction in Mice

  2026-07-15

  This study demonstrates that myriocin, a serine palmitoyltransferase inhibitor, restores metabolic homeostasis in mice exposed to diet-derived advanced glycation end products (dAGEs) by activating the AMPK-PGC1α pathway and enhancing mitochondrial biogenesis. The findings reveal a multifaceted mechanism for targeting obesity and metabolic syndrome through sphingolipid metabolism modulation.

• Solving Assay Challenges with Cy5 Goat Anti-Rabbit IgG (H+L)

  2026-07-15

  This article addresses real-world laboratory challenges in cell viability and immunofluorescence assays, demonstrating how the Cy5 Goat Anti-Rabbit IgG (H+L) Antibody (SKU K1212) ensures robust, reproducible signal amplification. By integrating scenario-driven Q&A, it highlights evidence-based workflow optimizations and reliable protocol parameters for advanced fluorescence detection.

• Oltipraz as a Chemopreventive Agent: Workflows for MASLD Mod

  2026-07-14

  Oltipraz, a potent Nrf2 pathway activator and glutathione S-transferase inducer, enables advanced modeling of metabolic associated steatotic liver disease (MASLD) and chemopreventive workflows. This article translates recent mechanistic breakthroughs—particularly in autophagy activation and ferroptosis inhibition—into practical protocols, optimization strategies, and troubleshooting guidance for hepatic researchers.

• Angiotensin I: Precision Workflows in Cardiovascular Researc

  2026-07-14

  Angiotensin I (human, mouse, rat) from APExBIO enables rigorous modeling of the renin-angiotensin system and high-fidelity antihypertensive drug screening. This guide delivers actionable protocols, troubleshooting strategies, and insights from cutting-edge spectral analysis to maximize reliability in cardiovascular and neuroendocrine studies.

• Protease Inhibitor Cocktail EDTA-Free: Precision in Protein

  2026-07-13

  Unlock consistent protein integrity during extraction and signaling studies with the Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO). This EDTA-free formulation safeguards against broad-spectrum protease activity without interfering with phosphorylation analysis, enabling robust workflows in both basic and translational research.

• PLGA Nano-Adjuvant Enhances Mucosal Immunity in H9N2 Vaccine

  2026-07-13

  A novel PLGA-based nanoadjuvant (PEI-LSP-RA-PLGA) enables targeted intestinal delivery and sustained antigen release, significantly amplifying both mucosal and systemic immune responses in chicks vaccinated against H9N2 avian influenza. This approach addresses the persistent challenge of inadequate mucosal immunity observed with traditional adjuvants and demonstrates strong application potential for improving avian vaccine efficacy.

• Catalpol (N1352): Protocol and Workflow Guide for Disease Mo

  2026-07-12

  Catalpol (SKU N1352) is a natural iridoid glycoside widely applied in neuroprotection, osteoporosis, ischemic stroke, and liver fibrosis research. This guide details practical protocol parameters, QC workflow, and troubleshooting for researchers utilizing Catalpol, with explicit boundaries for its application. It is not intended for applications outside the supported preclinical disease models and should not be extrapolated to unrelated biological contexts.

• Entinostat (MS-275): Decoding Selective HDAC1/3 Inhibition i

  2026-07-10

  Explore the advanced scientific underpinnings of Entinostat (MS-275) as a selective HDAC1/3 inhibitor. This cornerstone article unveils how nuanced assay interpretation and in vitro innovation are reshaping cancer cell proliferation inhibition research.

• SR-202: Precision PPARγ Antagonist for Metabolic Research

  2026-07-09

  SR-202 empowers researchers to dissect PPARγ-driven pathways with unmatched selectivity and solubility, making it a preferred tool for advanced insulin resistance and obesity research. Its robust performance in macrophage polarization and adipogenesis models accelerates translational discoveries in immunometabolic disease.

• URB597 (KDS-4103): Reliable FAAH Inhibition for Endocannabin

  2026-07-09

  This article explores how URB597 (SKU A4372) addresses real-world challenges in endocannabinoid signaling, neuroinflammation, and neuroplasticity research. Using scenario-driven Q&A, it demonstrates how APExBIO's URB597 offers reproducible FAAH inhibition with validated workflow parameters, supporting robust cell-based and in vivo assays.

• HATU in Peptide Synthesis Chemistry: Protocols & Innovations

  2026-07-08

  HATU delivers unmatched efficiency and selectivity in amide bond formation, elevating peptide synthesis chemistry for both routine and complex targets. By integrating recent structural and workflow innovations, researchers can now achieve higher yields and rapid couplings with fewer side reactions—essential for modern drug discovery pipelines.

• AMG 9810: Potent TRPV1 Antagonist for Pain Mechanism Researc

  2026-07-08

  AMG 9810 is a nanomolar-potency TRPV1 antagonist widely used in pain and sensory neuron research. It selectively inhibits capsaicin-induced calcium influx and CGRP release, enabling robust in vitro and in vivo studies of TRPV1-mediated pathways. The compound’s solubility and stability profile are well characterized for laboratory workflows.

• Sex Differences in Cannabinoid Withdrawal: Insights from WIN

  2026-07-07

  This study investigates sex-specific somatic and anxiety-like behaviors in rats during withdrawal from the synthetic cannabinoid agonist WIN 55,212-2, using rimonabant (SR141716) to precipitate withdrawal. The findings reveal qualitative differences between males and females in withdrawal symptomatology, advancing mechanistic understanding of endocannabinoid system modulation relevant to addiction and withdrawal research.

9242 records 1/617 page Next 12345 下5页 Last page